Log In
BCIQ
Print this Print this
 

IFN-beta-CTP (intravenous) (MOD-9023)

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionIV long-acting formulation of interferon (IFN) beta-1a developed using Prolor's CTP technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationMultiple sclerosis (MS)
Indication DetailsTreat multiple sclerosis (MS)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today